Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

Also called NCT06834490

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 318 participants (enrolled count) (from the registry)
Sponsor
  • Pharmasoft Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06834490
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Russia, Uzbekistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06834490. Randomized; double masking; primary purpose treatment. Start 2019-11-05 (actual); primary completion 2020-12-08 (actual). Results posted on 2025-10-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
Acronym
MEMO
Condition
Chronic Cerebral Ischemia
Intervention (Drug)
Mexidol
Intervention (Drug)
Placebo
Lead sponsor
Pharmasoft (class: industry)

Record details

Record id
cardio:ct-nct06834490
Content hash
30fa6d42cb00620d4b97339bc37d7755891540d052ad3a67b1e1a19022bb3f2a